论文部分内容阅读
[目的]评价术后辅助化疗联合细胞因子诱导的杀伤细胞(CIK)免疫治疗在结直肠癌治疗中的作用。[方法]连续收集2006年3月至2009年12月接受结直肠癌根治术后行辅助化疗联合≥4次CIK治疗的65例患者为CIK治疗组,采用1∶1方法,并按照病理分期、肿瘤部位、年龄等因素选择同期结直肠癌根治术后单纯接受辅助化疗的65例患者为对照组。随访截止至2014年5月。t检验、χ2检验/Fisher精确检验比较两组临床资料。观察终点为无病生存期(DFS)和总生存期(OS)。[结果]CIK治疗组1、2、3、4、5年无病生存率分别为82%、55%、43%、34%、30%,而对照组分别为63%、31%、27%、20%、19%(P<0.05)。CIK治疗组中位DFS明显优于对照组(27个月vs 16个月,P<0.05)。CIK治疗组1、2、3、4、5年总生存率分别为98%、94%、80%、72%、66%,而对照组分别为95%、84%、63%、53%、45%(P<0.05)。CIK治疗组中位OS明显优于对照组(74个月vs 54个月,P<0.05)。CIK治疗是患者预后的影响因素(P<0.05)。亚组分析显示,≥9次治疗的患者OS优于<9次的患者(P<0.05)。[结论]结直肠癌根治术后联合CIK治疗能够显著改善预后,且增加CIK治疗次数可以使患者更大程度获益。
[Objective] To evaluate the effect of postoperative adjuvant chemotherapy combined with cytokine-induced killer (CIK) immunotherapy in the treatment of colorectal cancer. [Methods] Sixty-five patients with CIK treated with adjuvant chemotherapy plus ≥4 CIKs after radical resection of colorectal cancer from March 2006 to December 2009 were enrolled in CIK treatment group. The patients were divided into three groups according to the pathological stage, Tumor site, age and other factors Select the same period of radical resection of colorectal cancer patients receiving chemotherapy alone in the control group. Follow-up until May 2014. t test, χ2 test / Fisher exact test comparing two groups of clinical data. Endpoints were disease-free survival (DFS) and overall survival (OS). [Results] The 1, 2, 3, 4, 5-year disease-free survival rates in CIK treatment group were 82%, 55%, 43%, 34% and 30%, respectively, while those in the control group were 63%, 31% and 27% , 20%, 19% (P <0.05). The median DFS in CIK treatment group was significantly better than that in control group (27 months vs 16 months, P <0.05). The overall survival rates at 1, 2, 3, 4, 5 years were 98%, 94%, 80%, 72% and 66% in the CIK group compared with 95%, 84%, 63% and 53% 45% (P <0.05). The median OS in CIK treatment group was significantly better than that in control group (74 months vs. 54 months, P <0.05). CIK treatment is a prognostic factor (P <0.05). Subgroup analyzes showed that the OS was> 9 times better than that of patients <9 (P <0.05). [Conclusion] Combination therapy with CIK after radical resection of colorectal cancer can significantly improve the prognosis, and increasing the number of CIK treatment can benefit patients to a greater extent.